HR Execs on the Move

Kinnate

www.kinnate.com

 
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kinnate.com
  • 12830 El Camino Real Suite 150
    San Diego, CA USA 92130
  • Phone: 858.299.4699

Executives

Name Title Contact Details
Nicole Doherty
Director, People and Culture Profile

Similar Companies

Organovo

Organovo (NYSE MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and other outlets. Organovo is changing the shape of medical research and practice.

HyperOmics Farma

HyperOmics Farma Inc. is a MontríŠal, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

IntegenX

IntegenX is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmative

Pharmative is a Northridge, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.